IXICO (LSE:IXI) has presented research on reducing scanner- and site-related variability in brain Volume measurements from Huntington's disease patients, concluding that validation matters more than simply minimising variability.

What was announced

IXICO plc, the AIM-quoted neuroscience imaging and biomarker analytics company, said on 29 October 2026 that it had presented new research at the European Huntington's Disease Network (EHDN) Clinical Research Congress 2026. The release was issued through a non-regulatory press release service, rather than as a regulatory announcement.

The research examined a novel method for reducing unwanted differences in brain volume measurements taken from people with Huntington's disease (HD). Such differences can arise when patients are scanned on different MRI machines, with different equipment, or at different clinical sites, a common situation in multi-centre clinical trials.

The findings

The central conclusion was that validating imaging methods and preserving clinically relevant information matter more than simply driving down measurement variability. According to IXICO, lower variability does not automatically improve the ability to track disease progression. In other words, a harmonisation technique that makes measurements look more consistent could, if not properly validated, also strip out some of the biological signal that trials are trying to detect.

The work used data from the Huntington's Disease Imaging Harmonisation (HD-IH) consortium. IXICO is a founding member of the consortium, which also includes leading biopharmaceutical companies and the CHDI Foundation. The release does not give detailed statistics, sample sizes for this specific study or the names of individual trials, but a summary is available on the company's Scientific Publications page.

IXICO said that, within its Huntington's disease work, it has analysed more than 6,000 MRI scans from over 2,000 participants using its proprietary, AI-powered IXI platform.

Chief scientific officer Robin Wolz explained the context: "In Huntington's clinical trials, researchers measure changes in brain structures to monitor disease progression." He said the findings demonstrate the importance of ensuring that imaging biomarkers reliably capture those changes, and that the research strengthens IXICO's position in Huntington's disease and its commitment to supporting more effective trials and new treatments.

Background

IXICO describes itself as a global leader in neuroscience imaging and biomarker analytics and as an end-to-end imaging contract research organisation, or iCRO. It provides imaging services to pharmaceutical and biotechnology companies running Clinical Trials in neurological conditions.

The company cites a 20-year track record, says it has supported hundreds of neurological trials and has analysed hundreds of thousands of scans. Beyond Huntington's disease, its platform covers Alzheimer's disease and Parkinson's disease, both of which are large areas of clinical development where brain imaging is widely used to measure treatment effects.

Huntington's disease is an inherited neurodegenerative condition, and imaging measures of brain structure are among the tools used in trials to track how the disease advances. Methods that make data from different sites comparable are important because large trials typically recruit across many hospitals and countries, each with its own scanning equipment.

What to watch next

The release contains no financial information, contract announcements or changes to guidance, and it does not quantify any commercial impact from the research. Its significance for IXICO is primarily scientific and reputational, supporting the company's positioning with sponsors running Huntington's disease studies.

Investors looking for the commercial picture will need to wait for IXICO's regular trading and results updates, where revenue, order book and contract wins are reported. The company did not indicate when further research from the HD-IH consortium might be presented. Contacts named in the release were chief financial officer Grant Nash and chief Business officer James Chandler, with Cavendish Capital Markets acting as nominated adviser and sole broker.